GlassScriptPhysician profile
Crystal G Privette
NPI 1639360290
$1,791.73
in general payments reported to CMS, 2019-2025
28 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $231 · 2021: $537 · 2022: $199 · 2023: $230 · 2024: $208 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $278.63 | 2021 | |
| Abbvie INC. | $232.79 | 2019-2025 | |
| Pfizer INC. | $188.09 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $152.70 | 2023-2025 | Gemtesa, Myfembree |
| Novo Nordisk INC | $112.13 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $94.79 | 2021-2024 | Veozah |
| Organon LLC | $85.01 | 2022-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $72.44 | 2020-2025 | Gardasil 9, Gardasil |
| Minerva Surgical, INC | $69.28 | 2020-2025 | |
| Allergan, INC. | $58.74 | 2019-2020 | |
| Therapeuticsmd, INC. | $54.60 | 2020-2021 | |
| Evofem Biosciences, INC. | $42.88 | 2021 | |
| Lilly USA, LLC | $41.86 | 2024 | Zepbound |
| Amag Pharmaceuticals, INC. | $40.64 | 2019 | |
| Exeltis, USA INC. | $40.03 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.10 | 2020-2021 | |
| Ascend Therapeutics US, LLC | $22.75 | 2023 | |
| Myovant Sciences INC. | $21.60 | 2021 | |
| Hologic Sales and Service, LLC | $21.05 | 2022 | |
| Agile Therapeutics, INC. | $18.44 | 2022 | |
| Scynexis, INC. | $17.24 | 2022 | |
| Avion Pharmaceuticals | $16.68 | 2023 | Balcoltra |
| Amgen INC. | $15.59 | 2019 | |
| Urovant Sciences INC | $15.53 | 2022 | |
| Adlon Therapeutics L.P. | $14.18 | 2020 | |
| Roche Diagnostics Corporation | $13.80 | 2021 | |
| Glaxosmithkline, LLC. | $11.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Privette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.